210
Participants
Start Date
April 30, 2006
Primary Completion Date
July 31, 2007
Study Completion Date
July 31, 2007
ipilimumab (MDX-010, BMS-734016)
IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
Ipilimumab
IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
Ipilimumab
IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
Local Institution, Brussels
Local Institution, Brussels
Local Institution, Brussels
Local Institution, Johannesburg
Local Institution, Newcastle
Local Institution, Heidelberg
Local Institution, Wodonga
Local Institution, Brisbane
Local Institution, Cape Town
Local Institution, Pécs
Memorial Sloan Kettering Cancer Center, New York
Local Institution, Berlin
Local Institution, Marseille
Local Institution, Jaú
Harry And Jeanette Weinberg Cancer Inst At Franklin Square, Baltimore
Local Institution, Kiel
Presbyterian Hospital, Charlotte
Local Institution, Brest
Cancer Centers Of The Carolinas, Greenville
Local Institution, Toulouse
Baptist Cancer Institute, Jacksonville
Md Anderson Cancer Center Orlando, Orlando
Mount Sinai Comprehensive Cancer Center, Miami Beach
Palm Beach Cancer Institute, West Palm Beach
Local Institution, Rennes
University Of Louisville, Louisville
Cleveland Clinic, Cleveland
Local Institution, Essen
The Christ Hospital Cancer Center Research, Cincinnati
American Health Network, Indianapolis
Local Institution, Vandœuvre-lès-Nancy
Hubert H. Humphrey Cancer Center, Robbinsdale
Oncology Specialists, Sc, Park Ridge
Local Institution, Clermont-Ferrand
Washington University School Of Medicine, St Louis
St Joseph Oncology Inc, Saint Joseph
Ellis Fischel Cancer Center, Columbia
Local Institution, Mannheim
Local Institution, Heidelberg
Local Institution, Lyon
Local Institution, Lyon
Local Institution, Paris
Center For Oncology Research & Treatment, P.A., Dallas
Mary Crowley Medical Research Center, Dallas
Arizona Cancer Center, Tucson
Local Institution, Centro-Porto Alegre
The Angeles Clinic And Research Institution, Santa Monica
Local Institution, Porto Alegre
Wilshire Oncology Medical Group Inc, Laverne
Scripps Cancer Center, San Diego
Local Institution, Würzburg
Providence Portland Medical Center, Portland
Yale University School Of Medicine, New Haven
Local Institution, São Paulo
Local Institution, Calgary
Local Institution, Edmonton
Local Institution, Kingston
Local Institution, Olomouc
Local Institution, Prague
Local Institution, Jena
Local Institution, Pretoria
Local Institution, Pretoria
Lead Sponsor
Collaborators (1)
Medarex
INDUSTRY
Bristol-Myers Squibb
INDUSTRY